• Ajoutez une description, des images, des menus et des liens à votre méga-menu

  • Une colonne sans paramètres peut être utilisée comme un espaceur

  • Lien vers vos collections, vos ventes et même des liens externes

  • Ajoutez jusqu'à cinq colonnes

  • février 25, 2026 2 lire la lecture

    Maternal infection is a significant cause of maternal illness and death worldwide. It is
    associated with as many as half of in-hospital maternal deaths, with the greatest burden
    observed in low- and middle-income countries where early detection and treatment remain challenging. Outcomes are especially poor in cases involving maternal sepsis. A landmark trial, the APT-Sepsis trial, published in the New England Journal of Medicine shows that a practical, low-cost intervention can dramatically reduce these preventable deaths.

    What is FAST-M?

    FAST-M is a maternal sepsis care bundle designed specifically for resource-limited settings. The acronym guides healthcare providers through five critical steps:

    • Fluids
    • Antibiotics
    • Source control
    • Transfer (if needed)
    • Monitoring of mother and baby

    The APT-Sepsis Trial Results

    The Active Prevention and Treatment of Maternal Sepsis (APT-Sepsis) trial scaled up this
    approach across 59 hospitals in Malawi and Uganda, with 30 assigned to the intervention group (15 in Malawi and 15 in Uganda) and 29 to the usual-care group (15 and 14, respectively), involving 431,394 women. The intervention combined three goals:

    1. to improve hand-hygiene adherence,
    2. to improve the prevention and management of maternal infection, and
    3. to increase early recognition and bundled treatment of sepsis (FAST-M)

    Key findings:

    • Implementation of the APT-Sepsis program led to a significantly lower risk of a
      composite outcome of infection-related maternal death, infection-related near-miss event, or severe infection-related illness than usual care.
    • For each of the goals the intervention of the APT-Sepsis program:

    o Increased hand hygiene compliance by 14%
    o Improved prevention in management of maternal infection via appropriate
    antibiotic prophylaxis use by 15%
    o Increased early recognition (32%) and bundled treatment of sepsis (8%)

    • Effectiveness increased over time, with increased success by the final month of the trial.
    • Results were consistent across both countries.
    • No costly new resources required.


    Why It Works in Low-Resource Settings

    Unlike many maternal health interventions, APT-Sepsis was designed from the ground up for feasibility in resource-constrained environments. The program:

    • Embeds within existing health systems
    • Uses readily available medications and supplies
    • Provides clear decision-making tools for frontline staff
    • Requires minimal additional training

    The intervention leverages modified early warning scores to track vital signs and trigger the FAST-M protocol when sepsis is suspected—a systematic approach that replaces inconsistent practices with standardized care.

    Looking Ahead

    These results demonstrate that structured, system-level interventions can overcome
    longstanding barriers in maternal sepsis care. The low-cost, sustainable model is
    designed for rapid scale-up through national and international health programs.
    Extending this intervention to other countries and settings may require partnering with
    national ministries of health, as in this trial, to facilitate uptake of the intervention and
    to adapt materials and processes to ensure they are culturally and contextually
    appropriate.

    Further work is needed to evaluate patient and provider experiences, behavior changes,
    and the cost-effectiveness of the intervention.

    Read the full study:

    "A Multicomponent Intervention to Improve Maternal Infection Outcomes"
    in the New England Journal of Medicine (2025)

     By Brittany de Soto Palmer

    Laisser un commentaire

    Les commentaires sont approuvés avant leur publication.


    Voir l'article entier

    Medical Devices for Hospitals and NGOs: How to Source the Right products for Maternal and Newborn Care
    Dispositifs médicaux pour les hôpitaux et les ONG : comment acheter les bons produits pour les soins maternels et néonatals

    juin 30, 2026 13 lire la lecture

    Voir l'article entier
    The High Quality Maternova Non-pneumatic anti-shock garment (NASG)
    Le vêtement antichoc non pneumatique (NASG) Maternova de haute qualité

    mai 25, 2026 1 lire la lecture

    Des vêtements antichoc non-pneumatiques (NASG) de haute qualité, conformes à la norme ISO 13485 et marqués CE, produits par Maternova pour être utilisés par les sages-femmes et les obstétriciens du monde entier afin de sauver des vies menacées par l'hémorragie post-partum. Nos NASG respectent les normes les plus strictes et sont approuvés par des centaines de cliniciens.

    Voir l'article entier
    A $.03 pill that could prevent maternal deaths; Part 4
    Une pilule à 0,03 $ qui pourrait prévenir les décès maternels ; 4ème partie

    mai 25, 2026 3 lire la lecture

    L'USPSTF, l'ACOG, la Society for Maternal-Fetal Medicine et la FIGO recommandent toutes l'aspirine à faible dose (LDA) pour les grossesses à haut risque. Les obstacles sont systémiques, comportementaux et structurels.

    Voir l'article entier